

HOMBURGER ADVISES ADC THERAPEUTICS IN ITS FOLLOW-ON PUBLIC OFFERING IN THE UNITED STATES

Posted on 25 September 2020



Category: [Deal & transactions](#)

Tags: [Benjamin Leisinger](#), [Daniel Häusermann](#), [Dieter Gericke](#), [Estelle Piccard](#), [Ex-Featured](#), [Homburger](#), [Marc Vogelsang](#), [Olivier Baum](#), [Reto Heuberger](#)



ADC Therapeutics, a Swiss-based late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of antibody drug conjugates, announced the pricing of its upsized follow-on public offering of shares in the United States, thus raising gross proceeds of USD 204 m. In addition, certain existing shareholders had granted the underwriters an option to purchase additional shares for an aggregate amount of up to USD 30.6 m.

The team

Homburger [advises ADC Therapeutics in this transaction](#). The team is led by partner Dieter Gericke (Corporate/M&A) and includes lead associate Daniel Häusermann (Corporate/ M&A), partners Reto Heuberger (Tax) and Benjamin Leisinger (Banking and Finance), as well as associates Olivier Baum (Banking and Finance), Estelle Piccard (Corporate/M&A) and Marc Vogelsang (Tax).